FT.com / Companies / Pharmaceuticals - Health study deals further blow to GSK’s Avandia
David Graham, a researcher at the US regulatory agency, concluded that among 227,000 diabetics aged over 65 in the 10 years until June 2009, those taking rosiglitazone (known by the brand name Avandia) had a 27 per cent greater risk of stroke, 25 per cent greater risk of heart failure and 13 per cent higher risk of death than those taking rival drug Acatos (pioglitazone) made by Takeda.
No comments:
Post a Comment